The agreements covers Zealand's drug, petrelintide, which works by mimicking the amylin hormone. Amylin is co-secreted with insulin. In theory, these drugs could preserve lean muscle mass better ...

Zealand Pharma begins patient enrolment in phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes: Copenhagen, Denmark Saturday, April 2 ...

The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug with fewer ...

Amylin analogs have been long pointed to as the next-generation of weight loss drugs. Amylin is a hormone secreted by pancreatic beta cells and analogs mimic the hormone to be co-secreted with insulin ...

In November, Amylin announced a $1 billion partnership with Osaka, Japan–based Takeda to codevelop and commercialize obesity treatments. Takeda paid the San Diego–based biotech $75 million ...

Amylin is a hormone that gives a feeling of fullness in the brain that suppresses appetite, reduces food intake, and delays gastric emptying. In a six-week, phase 1 study reported last year ...

It has been announced that following Bristol-Myers Squibb’s (BMS) successful acquisition of Amylin Pharmaceuticals, AstraZeneca (AZ) has made an initial payment of approximately US $3.2 billion ...

The effects of various agents targeting these gastrointestinal peptide systems, as shown in preclinical studies, are compared in Table 1. Enough experience from large clinical trials has been ...

Both Ozempic and Zepbound target the GLP-1 hormone. By contrast, GUBamy acts as an analog of the body’s amylin hormone. Amylin has been identified as a potential therapeutic target for obesity ...

Examples of gastrointestinal hormones are ghrelin, amylin and glucagon-like peptides 1 and 2. FGF19 increase in post-bariatric hypoglycaemia is mediated by bile acid dysregulation, and can be ...